NCT01282463 2019-09-09Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaEli Lilly and CompanyPhase 2 Completed148 enrolled 19 charts